Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
Weaver AN, Iams WT, Park JC, Mita M, Holtick U, Gordon MS, Rodabaugh KJ, Dhani N, Neupane P, Taylor M, Amanda Duvall E, Jennings J, Miselis NR, Loughhead S, Warren MS, Bernstein H, Klussmann JP, Baranda J, Jimeno A.
Weaver AN, et al.
Mol Carcinog. 2024 Aug;63(8):1421-1428. doi: 10.1002/mc.23738. Epub 2024 May 2.
Mol Carcinog. 2024.
PMID: 38695604
Clinical Trial.